• Je něco špatně v tomto záznamu ?

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

MJGW. Ladds, IMM. van Leeuwen, CJ. Drummond, S. Chu, AR. Healy, G. Popova, A. Pastor Fernández, T. Mollick, S. Darekar, SK. Sedimbi, M. Nekulova, MCC. Sachweh, J. Campbell, M. Higgins, C. Tuck, M. Popa, MM. Safont, P. Gelebart, Z. Fandalyuk, AM....

. 2018 ; 9 (1) : 1107. [pub] 20180316

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024297

The development of non-genotoxic therapies that activate wild-type p53 in tumors is of great interest since the discovery of p53 as a tumor suppressor. Here we report the identification of over 100 small-molecules activating p53 in cells. We elucidate the mechanism of action of a chiral tetrahydroindazole (HZ00), and through target deconvolution, we deduce that its active enantiomer (R)-HZ00, inhibits dihydroorotate dehydrogenase (DHODH). The chiral specificity of HZ05, a more potent analog, is revealed by the crystal structure of the (R)-HZ05/DHODH complex. Twelve other DHODH inhibitor chemotypes are detailed among the p53 activators, which identifies DHODH as a frequent target for structurally diverse compounds. We observe that HZ compounds accumulate cancer cells in S-phase, increase p53 synthesis, and synergize with an inhibitor of p53 degradation to reduce tumor growth in vivo. We, therefore, propose a strategy to promote cancer cell killing by p53 instead of its reversible cell cycle arresting effect.

Centre for Cancer Biomarkers CCBIO Department of Clinical Science Hematology Section University of Bergen 5021 Bergen Norway

Centre for Cancer Biomarkers CCBIO Department of Clinical Science Hematology Section University of Bergen 5021 Bergen Norway Department of Medicine Haematology Section Haukeland University Hospital Bergen Norway

Centre for Oncology and Molecular Medicine University of Dundee Ninewells Hospital and Medical School Dundee Tayside DD1 9SY UK

Chemical Biology Consortium Sweden Science for Life Laboratory Division of Translational Medicine and Chemical Biology Department of Medical Biochemistry and Biophysics Karolinska Institutet SE 171 21 Stockholm Sweden

Department of Breast Surgical Oncology MD Anderson Cancer Center Holcombe Boulevard Houston 77030 USA

Department of Medicinal Chemistry Science for Life Laboratories Uppsala University SE 751 23 Uppsala Sweden

Department of Microbiology Tumor and Cell Biology Karolinska Institutet SE 171 77 Stockholm Sweden

Department of Microbiology Tumor and Cell Biology Karolinska Institutet SE 171 77 Stockholm Sweden RECAMO Masaryk Memorial Cancer Institute Zluty Kopec 7 65653 Brno Czech Republic

Department of Microbiology Tumor and Cell Biology Karolinska Institutet Tomtebodavägen 23 SE 171 21 Stockholm Sweden

Department of Pharmacy Uppsala University Drug Optimization and Pharmaceutical Profiling Platform Department of Pharmacy Uppsala University SE 752 37 Uppsala Sweden

Division of Hematology and Oncology Comprehensive Cancer Center 1720 2nd Avenue South NP2540 Birmingham AL 35294 3300 USA

Drug Discovery and Development Platform Science for Life Laboratory Tomtebodavägen 23 SE 171 21 Solna Sweden

Newcastle Cancer Centre Northern Institute for Cancer Research Newcastle University Newcastle NE1 7RU UK

RECAMO Masaryk Memorial Cancer Institute Zluty Kopec 7 65653 Brno Czech Republic

SARomics Biostructures Medicon Village SE 223 81 Lund Sweden

School of Chemistry and Biomedical Sciences Research Complex University of St Andrews and EaStCHEM St Andrews Fife Scotland KY16 9ST UK

SciLifeLab Department of Microbiology Tumor and Cell Biology Karolinska Institutet Tomtebodavägen 23 SE 171 21 Stockholm Sweden

The Wellcome Trust Centre for Cell Biology Institute of Cell Biology University of Edinburgh Edinburgh EH9 3JR UK

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024297
003      
CZ-PrNML
005      
20180710093637.0
007      
ta
008      
180709s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41467-018-03441-3 $2 doi
035    __
$a (PubMed)29549331
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ladds, Marcus J G W $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.
245    12
$a A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage / $c MJGW. Ladds, IMM. van Leeuwen, CJ. Drummond, S. Chu, AR. Healy, G. Popova, A. Pastor Fernández, T. Mollick, S. Darekar, SK. Sedimbi, M. Nekulova, MCC. Sachweh, J. Campbell, M. Higgins, C. Tuck, M. Popa, MM. Safont, P. Gelebart, Z. Fandalyuk, AM. Thompson, R. Svensson, AL. Gustavsson, L. Johansson, K. Färnegårdh, U. Yngve, A. Saleh, M. Haraldsson, ACA. D'Hollander, M. Franco, Y. Zhao, M. Håkansson, B. Walse, K. Larsson, EM. Peat, V. Pelechano, J. Lunec, B. Vojtesek, M. Carmena, WC. Earnshaw, AR. McCarthy, NJ. Westwood, M. Arsenian-Henriksson, DP. Lane, R. Bhatia, E. McCormack, S. Laín,
520    9_
$a The development of non-genotoxic therapies that activate wild-type p53 in tumors is of great interest since the discovery of p53 as a tumor suppressor. Here we report the identification of over 100 small-molecules activating p53 in cells. We elucidate the mechanism of action of a chiral tetrahydroindazole (HZ00), and through target deconvolution, we deduce that its active enantiomer (R)-HZ00, inhibits dihydroorotate dehydrogenase (DHODH). The chiral specificity of HZ05, a more potent analog, is revealed by the crystal structure of the (R)-HZ05/DHODH complex. Twelve other DHODH inhibitor chemotypes are detailed among the p53 activators, which identifies DHODH as a frequent target for structurally diverse compounds. We observe that HZ compounds accumulate cancer cells in S-phase, increase p53 synthesis, and synergize with an inhibitor of p53 degradation to reduce tumor growth in vivo. We, therefore, propose a strategy to promote cancer cell killing by p53 instead of its reversible cell cycle arresting effect.
650    _2
$a antitumorózní látky $x farmakologie $7 D000970
650    _2
$a buněčný cyklus $x účinky léků $7 D002453
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a inhibitory enzymů $x farmakologie $7 D004791
650    _2
$a lidé $7 D006801
650    _2
$a indazoly $x farmakologie $7 D007191
650    _2
$a nádory $x farmakoterapie $x enzymologie $x genetika $x metabolismus $7 D009369
650    _2
$a oxidoreduktasy působící na CH-CH vazby $x antagonisté a inhibitory $x chemie $x genetika $x metabolismus $7 D044925
650    _2
$a proteolýza $x účinky léků $7 D059748
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a van Leeuwen, Ingeborg M M $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Drummond, Catherine J $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Chu, Su $u Division of Hematology and Oncology, Comprehensive Cancer Center, 1720 2nd Avenue South, NP2540, Birmingham, AL, 35294-3300, USA.
700    1_
$a Healy, Alan R $u School of Chemistry and Biomedical Sciences Research Complex, University of St. Andrews and EaStCHEM, St. Andrews, Fife, Scotland, KY16 9ST, UK.
700    1_
$a Popova, Gergana $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Pastor Fernández, Andrés $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Mollick, Tanzina $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.
700    1_
$a Darekar, Suhas $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.
700    1_
$a Sedimbi, Saikiran K $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.
700    1_
$a Nekulova, Marta $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. RECAMO, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 65653, Brno, Czech Republic.
700    1_
$a Sachweh, Marijke C C $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Campbell, Johanna $u Centre for Oncology and Molecular Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Tayside, DD1 9SY, UK.
700    1_
$a Higgins, Maureen $u Centre for Oncology and Molecular Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Tayside, DD1 9SY, UK.
700    1_
$a Tuck, Chloe $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Popa, Mihaela $u Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, Hematology Section, University of Bergen, 5021, Bergen, Norway.
700    1_
$a Safont, Mireia Mayoral $u Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, Hematology Section, University of Bergen, 5021, Bergen, Norway.
700    1_
$a Gelebart, Pascal $u Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, Hematology Section, University of Bergen, 5021, Bergen, Norway.
700    1_
$a Fandalyuk, Zinayida $u Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, Hematology Section, University of Bergen, 5021, Bergen, Norway.
700    1_
$a Thompson, Alastair M $u Department of Breast Surgical Oncology, MD Anderson Cancer Center, Holcombe Boulevard, Houston, 77030, USA.
700    1_
$a Svensson, Richard $u Department of Pharmacy, Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Department of Pharmacy, Uppsala University, SE-752 37, Uppsala, Sweden.
700    1_
$a Gustavsson, Anna-Lena $u Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 21, Stockholm, Sweden.
700    1_
$a Johansson, Lars $u Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 21, Stockholm, Sweden.
700    1_
$a Färnegårdh, Katarina $u Drug Discovery and Development Platform, Science for Life Laboratory, Tomtebodavägen 23, SE-171 21, Solna, Sweden.
700    1_
$a Yngve, Ulrika $u Department of Medicinal Chemistry, Science for Life Laboratories, Uppsala University, SE-751 23, Uppsala, Sweden.
700    1_
$a Saleh, Aljona $u Department of Medicinal Chemistry, Science for Life Laboratories, Uppsala University, SE-751 23, Uppsala, Sweden.
700    1_
$a Haraldsson, Martin $u Drug Discovery and Development Platform, Science for Life Laboratory, Tomtebodavägen 23, SE-171 21, Solna, Sweden.
700    1_
$a D'Hollander, Agathe C A $u School of Chemistry and Biomedical Sciences Research Complex, University of St. Andrews and EaStCHEM, St. Andrews, Fife, Scotland, KY16 9ST, UK.
700    1_
$a Franco, Marcela $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Zhao, Yan $u Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle, NE1 7RU, UK.
700    1_
$a Håkansson, Maria $u SARomics Biostructures, Medicon Village, SE-223 81, Lund, Sweden.
700    1_
$a Walse, Björn $u SARomics Biostructures, Medicon Village, SE-223 81, Lund, Sweden.
700    1_
$a Larsson, Karin $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Peat, Emma M $u The Wellcome Trust Centre for Cell Biology, Institute of Cell Biology, University of Edinburgh, Edinburgh, EH9 3JR, UK.
700    1_
$a Pelechano, Vicent $u SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.
700    1_
$a Lunec, John $u Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle, NE1 7RU, UK.
700    1_
$a Vojtesek, Borivoj $u RECAMO, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 65653, Brno, Czech Republic.
700    1_
$a Carmena, Mar $u The Wellcome Trust Centre for Cell Biology, Institute of Cell Biology, University of Edinburgh, Edinburgh, EH9 3JR, UK.
700    1_
$a Earnshaw, William C $u The Wellcome Trust Centre for Cell Biology, Institute of Cell Biology, University of Edinburgh, Edinburgh, EH9 3JR, UK.
700    1_
$a McCarthy, Anna R $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Westwood, Nicholas J $u School of Chemistry and Biomedical Sciences Research Complex, University of St. Andrews and EaStCHEM, St. Andrews, Fife, Scotland, KY16 9ST, UK.
700    1_
$a Arsenian-Henriksson, Marie $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
700    1_
$a Lane, David P $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.
700    1_
$a Bhatia, Ravi $u Division of Hematology and Oncology, Comprehensive Cancer Center, 1720 2nd Avenue South, NP2540, Birmingham, AL, 35294-3300, USA.
700    1_
$a McCormack, Emmet $u Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, Hematology Section, University of Bergen, 5021, Bergen, Norway. Department of Medicine, Haematology Section, Haukeland University Hospital, Bergen, Norway.
700    1_
$a Laín, Sonia $u Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. sonia.lain@ki.se. SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden. sonia.lain@ki.se.
773    0_
$w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 9, č. 1 (2018), s. 1107
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29549331 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180710093926 $b ABA008
999    __
$a ok $b bmc $g 1316428 $s 1021218
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c 1 $d 1107 $e 20180316 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace